Literature DB >> 28068329

The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.

A Pemov1, H Li2, R Patidar3, N F Hansen4, S Sindiri3, S W Hartley5, J S Wei3, A Elkahloun4, S C Chandrasekharappa4, J F Boland6, S Bass6, J C Mullikin4,7, J Khan3, B C Widemann8, M R Wallace2, D R Stewart1.   

Abstract

Neurofibromatosis type 1 (NF1) is a common tumor-predisposition disorder due to germline mutations in the tumor suppressor gene NF1. A virtually pathognomonic finding of NF1 is the plexiform neurofibroma (PN), a benign, likely congenital tumor that arises from bi-allelic inactivation of NF1. PN can undergo transformation to a malignant peripheral nerve sheath tumor, an aggressive soft-tissue sarcoma. To better understand the non-NF1 genetic contributions to PN pathogenesis, we performed whole-exome sequencing, RNASeq profiling and genome-wide copy-number determination for 23 low-passage Schwann cell cultures established from surgical PN material with matching germline DNA. All resected tumors were derived from routine debulking surgeries. None of the tumors were considered at risk for malignant transformation at the time; for example, there was no pain or rapid growth. Deep (~500X) NF1 exon sequencing was also conducted on tumor DNA. Non-NF1 somatic mutation verification was performed using the Ampliseq/IonTorrent platform. We identified 100% of the germline NF1 mutations and found somatic NF1 inactivation in 74% of the PN. One individual with three PNs had different NF1 somatic mutations in each tumor. The median number of somatic mutations per sample, including NF1, was one (range 0-8). NF1 was the only gene that was recurrently somatically inactivated in multiple tumors. Gene Set Enrichment Analysis of transcriptome-wide tumor RNA sequencing identified five significant (FDR<0.01) and seven trending (0.01⩽FDR<0.02) gene sets related to DNA replication, telomere maintenance and elongation, cell cycle progression, signal transduction and cell proliferation. We found no recurrent non-NF1 locus copy-number variation in PN. This is the first multi-sample whole-exome and whole-transcriptome sequencing study of NF1-associated PN. Taken together with concurrent copy-number data, our comprehensive genetic analysis reveals the primacy of NF1 loss as the driver of PN tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28068329      PMCID: PMC6689395          DOI: 10.1038/onc.2016.464

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  56 in total

1.  Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.

Authors:  Brian Weiss; Brigitte C Widemann; Pamela Wolters; Eva Dombi; Alexander A Vinks; Alan Cantor; Bruce Korf; John Perentesis; David H Gutmann; Elizabeth Schorry; Roger Packer; Michael J Fisher
Journal:  Pediatr Blood Cancer       Date:  2014-06       Impact factor: 3.167

2.  Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.

Authors:  Eline Beert; Hilde Brems; Bruno Daniëls; Ivo De Wever; Frank Van Calenbergh; Joseph Schoenaers; Maria Debiec-Rychter; Olivier Gevaert; Thomas De Raedt; Annick Van Den Bruel; Thomy de Ravel; Karen Cichowski; Lan Kluwe; Victor Mautner; Raf Sciot; Eric Legius
Journal:  Genes Chromosomes Cancer       Date:  2011-08-24       Impact factor: 5.006

3.  Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome.

Authors:  Catherine Dodé; Jacqueline Levilliers; Jean-Michel Dupont; Anne De Paepe; Nathalie Le Dû; Nadia Soussi-Yanicostas; Roney S Coimbra; Sedigheh Delmaghani; Sylvie Compain-Nouaille; Françoise Baverel; Christophe Pêcheux; Dominique Le Tessier; Corinne Cruaud; Marc Delpech; Frank Speleman; Stefan Vermeulen; Andrea Amalfitano; Yvan Bachelot; Philippe Bouchard; Sylvie Cabrol; Jean-Claude Carel; Henriette Delemarre-van de Waal; Barbara Goulet-Salmon; Marie-Laure Kottler; Odile Richard; Franco Sanchez-Franco; Robert Saura; Jacques Young; Christine Petit; Jean-Pierre Hardelin
Journal:  Nat Genet       Date:  2003-03-10       Impact factor: 38.330

4.  Cellular differentiation and expression of matrix genes in type 1 neurofibromatosis.

Authors:  J Peltonen; S Jaakkola; M Lebwohl; S Renvall; L Risteli; I Virtanen; J Uitto
Journal:  Lab Invest       Date:  1988-12       Impact factor: 5.662

5.  Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales.

Authors:  S M Huson; P S Harper; D A Compston
Journal:  Brain       Date:  1988-12       Impact factor: 13.501

6.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

7.  Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.

Authors:  Meena Upadhyaya; Gill Spurlock; Laura Thomas; Nick S T Thomas; Mark Richards; Viktor-Felix Mautner; David N Cooper; Abhijit Guha; Jim Yan
Journal:  Hum Mutat       Date:  2012-03-05       Impact factor: 4.878

8.  Differential expression of CCN1/CYR61, CCN3/NOV, CCN4/WISP1, and CCN5/WISP2 in neurofibromatosis type 1 tumorigenesis.

Authors:  Eric Pasmant; Nicolas Ortonne; Laure Rittié; Ingrid Laurendeau; Pascale Lévy; Vladimir Lazar; Béatrice Parfait; Karen Leroy; Philippe Dessen; Laurence Valeyrie-Allanore; Bernard Perbal; Pierre Wolkenstein; Michel Vidaud; Dominique Vidaud; Ivan Bièche
Journal:  J Neuropathol Exp Neurol       Date:  2010-01       Impact factor: 3.685

Review 9.  Contextual signaling in cancer.

Authors:  Laura J Smithson; Corina Anastasaki; Ran Chen; Joseph A Toonen; Sidney B Williams; David H Gutmann
Journal:  Semin Cell Dev Biol       Date:  2016-06-03       Impact factor: 7.727

10.  Identifying cancer driver genes in tumor genome sequencing studies.

Authors:  Ahrim Youn; Richard Simon
Journal:  Bioinformatics       Date:  2010-12-17       Impact factor: 6.937

View more
  38 in total

Review 1.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

Review 2.  Current status of MEK inhibitors in the treatment of plexiform neurofibromas.

Authors:  Andrea M Gross; Eva Dombi; Brigitte C Widemann
Journal:  Childs Nerv Syst       Date:  2020-06-30       Impact factor: 1.475

Review 3.  Molecular targets for NF1-associated malignant peripheral nerve sheath tumor.

Authors:  Lama Binobaid; Michal M Masternak
Journal:  Rep Pract Oncol Radiother       Date:  2020-04-27

Review 4.  Heterozygous Tumor Suppressor Microenvironment in Cancer Development.

Authors:  Jean-Philippe Brosseau; Lu Q Le
Journal:  Trends Cancer       Date:  2019-08-15

5.  Localized Hypertrophic Neuropathy as a Neoplastic Manifestation of KRAS-Mediated RASopathy.

Authors:  M Adelita Vizcaino; Allan Belzberg; Shivani Ahlawat; Sarra Belakhoua; Liam Chen; Verena Staedtke; Fausto J Rodriguez
Journal:  J Neuropathol Exp Neurol       Date:  2020-06-01       Impact factor: 3.685

6.  Comparative clinical and genomic analysis of neurofibromatosis type 2-associated cranial and spinal meningiomas.

Authors:  Alexander Pemov; Ramita Dewan; Nancy F Hansen; Settara C Chandrasekharappa; Abhik Ray-Chaudhury; Kristine Jones; Wen Luo; John D Heiss; James C Mullikin; Prashant Chittiboina; Douglas R Stewart; Ashok R Asthagiri
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

7.  Cxcr3-expressing leukocytes are necessary for neurofibroma formation in mice.

Authors:  Jonathan S Fletcher; Jianqiang Wu; Walter J Jessen; Jay Pundavela; Jacob A Miller; Eva Dombi; Mi-Ok Kim; Tilat A Rizvi; Kashish Chetal; Nathan Salomonis; Nancy Ratner
Journal:  JCI Insight       Date:  2019-02-07

Review 8.  Genetic Events and Signaling Mechanisms Underlying Schwann Cell Fate in Development and Cancer.

Authors:  Harish N Vasudevan; Calixto-Hope G Lucas; Javier E Villanueva-Meyer; Philip V Theodosopoulos; David R Raleigh
Journal:  Neurosurgery       Date:  2021-01-13       Impact factor: 4.654

9.  NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation.

Authors:  Yanan Yu; Kwangmin Choi; Jianqiang Wu; Paul R Andreassen; Phillip J Dexheimer; Mehdi Keddache; Hilde Brems; Robert J Spinner; Jose A Cancelas; Lisa J Martin; Margaret R Wallace; Eric Legius; Kristine S Vogel; Nancy Ratner
Journal:  Acta Neuropathol       Date:  2019-10-29       Impact factor: 17.088

10.  The molecular landscape of glioma in patients with Neurofibromatosis 1.

Authors:  Fulvio D'Angelo; Michele Ceccarelli; Luciano Garofano; Jing Zhang; Véronique Frattini; Francesca P Caruso; Genevieve Lewis; Kristin D Alfaro; Luc Bauchet; Giulia Berzero; David Cachia; Mario Cangiano; Laurent Capelle; John de Groot; Francesco DiMeco; François Ducray; Walid Farah; Gaetano Finocchiaro; Stéphane Goutagny; Carlos Kamiya-Matsuoka; Cinzia Lavarino; Hugues Loiseau; Véronique Lorgis; Carlo E Marras; Ian McCutcheon; Do-Hyun Nam; Susanna Ronchi; Veronica Saletti; Romuald Seizeur; John Slopis; Mariona Suñol; Fanny Vandenbos; Pascale Varlet; Dominique Vidaud; Colin Watts; Viviane Tabar; David E Reuss; Seung-Ki Kim; David Meyronet; Karima Mokhtari; Hector Salvador; Krishna P Bhat; Marica Eoli; Marc Sanson; Anna Lasorella; Antonio Iavarone
Journal:  Nat Med       Date:  2018-12-10       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.